Incyte Corporation · Wilmington, DE United States (NASDAQ: INCY)
| Experimental Station, Route 141 & Henry Clay Road, Bldg. E336 | Phone: 302-498-6700 |
| Wilmington, DE | Fax: 302-425-2750 |
| 19880 | |
| United States | 
Map This Company |
Incyte Corporation Rankings
Company Description
Incyte hopes its success with inhibitors is uninhibited. The biotechnology company is focused on discovering and developing drugs that inhibit specific enzymes associated with cancer, diabetes, blood disorders, and inflammatory diseases. The company's lead program is its JAK kinase inhibitor program, which covers treatments for inflammatory diseases and cancers, including rheumatoid arthritis, myelofibrosis, psoriasis, solid tumors, and breast cancer. Incyte's product candidates are in various stages of research and clinical trials, partially through partnerships with other drugmakers.
Incyte Corporation Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - NASDAQ: INCY Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 247 |
Executives
18 executives listed for Incyte Corporation's Wilmington, DE location.
| Chairman | Richard De Schutter | |
|---|---|---|
| President, CEO and Director | Paul Friedman | |
| EVP and CFO | David Hastings |